Introduction
Glycogen phosphorylase (GP), the main regulatory enzyme of the glycogen metabolism pathway, is a validated target to control 50 hepatic glucose output in noninsulin dependent or type 2 diabetes mellitus (T2DM).
1-3 T2DM is a major concern to public health 4, 5 with several long term complications 6 such as cardiovascular disease, neuropathy, retinopathy and nephropathy. Biochemical and pharmacological aspects of T2DM have been amply reviewed and for a detailed rationalization of the possible use of GP inhibitors (GPIs) as antidiabetics, the reader is kindly referred to those articles. [1] [2] [3] Besides T2DM, inhibition of GP has also been studied in connection with diseases caused by abnormalities in glycogen metabolism, 7, 8 such as myocardial ischemia 9 , cerebral ischemia 10 60 and tumors. 11, 12 Several types of compounds have been shown to inhibit this enzyme under in vitro conditions. 13 Among them the glucose based inhibitors targeting the catalytic site are the most extensively investigated derivatives [14] [15] [16] [17] and a glucopyranosylidene-spiro-thiohydantoin has been shown to have appreciable in vivo hypoglycaemic effects. and N-acyl-N 0 -b-D-glucopyranosyl ureas (II) 13, 22, 23 are among the best glucose analogue inhibitors of GP discovered to date, which 70 are efficient in or below the low micromolar range. Bioisosteric replacement is widely used in medicinal chemistry to design new drug molecules by systematic modification of lead compounds. 29 Nonclassical bioisosteric replacements of the NHCO moiety in I by heterocyclic linkers A-D (Chart 1) resulted in inhibitors of varying efficiency. [24] [25] [26] While 1,2,3-triazoles IA proved equipotent with the amides I, among oxadiazoles IB-D the constitution of the ring was decisive for the effect, and only ID was of similar efficiency as I. In these compounds the presence of a large hydrophobic aromatic ring was very advantageous for the inhibi-80 tion, and derivatives with a 2-naphthyl group were the best inhibitors in each series. Replacements of the 'second' amide moiety in II (highlighted in Chart 1) with heterocycles E and F were detrimental for the binding, but revealed that compounds with a phenyl group could bind stronger than those with a 2-naphthyl substituent. 28 As a continuation of our systematic structure-activity relationship studies 25, 26, 28, 30 on bioisosteric replacements of NHCO moieties in inhibitors I and II, we have now synthesised new oxadiazolecarboxamide derivatives IIB-D and evaluated through 90 kinetic experiments their potential for GP inhibition. In addition, prediction of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties was also performed to evaluate the drug-like potential of these derivatives.
Results and discussion

Syntheses
Preparation of the target compounds was envisaged and investigated by two possible routes (Scheme 1): formation of the amide C-N bond in a direct transformation of protected glucopyranosyl azide via acylation of the in situ generated iminophosphorane with 100 an oxadiazolecarboxylic acid or acid chloride, or equivalently, by acylation of glucopyranosylamine (route A), or heterocyclisation of suitable functional groups of the corresponding N-acylated glucopyranosylamine derivatives (route B).
To study synthetic routes A, preparation of the necessary oxadiazolecarboxylic acids was first attempted. Following a literature protocol, commercially available benzhydrazide (1) was ethoxalylated to give 2 (Scheme 2) which was closed to ethyl 5-phenyl-1,3,4-oxadiazole-2-carboxylate (3) in 47% yield. 31 Hydrolysis of 3 gave carboxylic acid 4 in 70% yield. 32 Synthesis of 1,2,4-oxadiaz-110 ole-carboxylic acids was also tried from the corresponding ethyl esters, 33 however, we were unable to reproduce the reported hydrolytic step 34 because of opening of the heterocycle.
Acylation of the glycosylimino-trimethylphosphorane obtained from 2,3,4,6-penta-O-acetyl-b-D-glucopyranosyl azide (6) with carboxylic acid 4 failed, however, oxadiazolecarboxamide derivative 10a could be prepared in 10% yield by using acid chloride 5.
In view of the low yield of this transformation and the failure of getting other oxadiazolecarboxylic acids, we turned to the The necessary 5-aryl-1,3,4-oxadiazole derivatives 10a-c were obtained from 9 by the corresponding aroyl chloride in dry toluene at elevated temperature 37 in moderate to good yields (10a: 80%;
10b: 74%, 10c: 30%). O-Deacetylations were performed by the Zemplén protocol to give excellent yields (up to 87%) of unpro-130 tected 1,3,4-oxadiazole derivatives 11a-c. Next, we turned to the synthesis of N-glucopyranosyl 5-aryl-1,2,4-oxadiazole-3-carboxamides 15a-c (Scheme 3). In a continuous operation, N-cyanocarbonyl derivative 8 was transformed into amidoxime 12 by NH 2 OH, followed by acylation with aroyl chlorides and ring closure in the presence TBAF to the desired 1,2,4-oxadiazole derivatives 14a-c in moderate overall yields (22-24%). Synthesis of 14a was also carried out via the isolated but unpurified 12 and fully characterized 13a in a two steps procedure, but the overall yield was similar (28% as compared to 24% by the one-pot 140 reaction). O-Deacetylations by the Zemplén protocol gave the unprotected 5-aryl-1,2,4-oxadiazole derivatives 15a-c in acceptable yields (49-64%).
Synthesis of N-glucopyranosyl 3-aryl-1,2,4-oxadiazole-5-carboxamides 20 was attempted by cycloaddition of nitrile-oxides to the CN group of 8, however, this resulted in an unseparable multicomponent product mixture. To get 20 in a less direct but one-pot procedure, acylation of glucopyranosylamine 7 was achieved with (COCl) 2 in dry THF (Scheme 4) to give the N-substituted oxamidoyl chloride 16. Next, freshly prepared arenecarboxamidoximes 18a- performed by the Zemplén protocol to give good (62-79%) yields of unprotected 3-aryl-1,2,4-oxadiazole derivatives 21a-c.
Enzyme inhibition studies
The kinetic parameters of the deprotected compounds (inhibition constants (K i ) against rabbit muscle glycogen phosphorylase b (RMGPb)) were determined according to the protocol described 160 earlier. 41 The results are summarized in Table 1 , together with the K i -s of relevant reference compounds.
The new N-glucopyranosyl oxadiazole-carboxamides showed inhibitory properties in a very broad range from inactive compounds to low micromolar inhibitors. The most remarkable observation was that the best compounds in the different series did not have the same aromatic moiety as it could have been expected from previous experiences. Thus, from 1,3,4-oxadiazoles 11, from 5-aryl-1,2,4-oxadiazoles 15, and from 3-aryl-1,2,4-oxadiazoles 21, the 2-naphthyl 11b, the 1-naphthyl 15c, and the phenyl 21a deriv-atives, respectively, were the best inhibitors. Since the size of the heterocycles must be very similar, this phenomenon might be due to variations of interactions between the oxadiazole rings and the enzyme as well as to the probably different orientations of the aromatic substituents. It is also worth noting that in two series the 2-naphthyl derivatives 15b and 21b were inactive, although this was similar to the cases of isoxazoles 22 and 1,2,3-triazoles 23. In comparison to the homoaromatic N-glucopyranosyl arenecarboxamides 24 the inhibition of the oxadiazolecarboxamides was generally weaker for the phenyl (a) and the 2-naphthyl (b) deriva-180 tives, while stronger for the 1-naphthyl (c) compounds. This may be attributed to the different size of the molecules and the orientation of the aromatic rings. Finally, a comparison to the 'parent' molecules 25 used as lead for the bioisosteric replacement showed a significant loss of the activity with each of the aromatic substituents. Molecular dockings to get a better insight in the structural details of the binding peculiarities of these and other heterocyclic N-glucopyranosyl carboxamides as well as to predict more efficient structures are in progress. 47 Therefore, toxicity structural warnings for our inhibitors were also probed using the FAF-Drugs2 server. 48 The results of our calculations are given in Table 2 . Property predictions that are outside the range observed for 95% of known drugs (QikProp, version 3.5, User Manual) are flagged with an asterisk ( will need attention in 'lead optimization' of any heterocylic derivative conjugated to glucose found to have attractive GP inhibitory potential (low lM activity or better).
ADMET properties calculations
The degree of plasma protein binding also affects the amount of bioavailable drug. Log K hsa is the prediction of the degree of binding to human serum albumin (hsa) and is satisfactory for all ligands ($1), within the range for 95% of known drugs (À1.5-1.5). Likewise, the predicted blood-brain barrier co-efficients (log BB values: À3.0-2.7) are within the desirable limits (À3.0-1.2). Finally, a complete lack of toxicity structural warnings from FAF-Drugs2 is encouraging 250 with respect to the toxicity profiles for conjugates of glucose and substituted heterocycles. 
Conclusions
Synthetic procedures were elaborated for all possible isomers of N-b-D-glucopyranosyl aryl-substituteD-oxadiazolecarboxamides. The compounds with phenyl, 1-and 2-naphthyl substituents were assayed against rabbit muscle GPb to show low micromolar efficiency for the best inhibitors. Both the constitution of the oxadiazole ring and the type of the aryl substituent had a strong bearing on the inhibition, and the best compounds of the different series were 11b 260 (K i = 30 lM), 15c (K i = 33 lM), and 21a (K i = 104 lM). ADMET property predictions revealed all ligands to have oral 'drug-like' properties based on Lipinski's 'rule of 5'. Apart from potential permeability issues which would require 'optimization' based on Jorgensens 'rule of three', the inhibitors had satisfactory pharmacokinetic profiles and were devoid of any toxicity structural warnings. The consideration of heterocyclic substitutions in N-b-D-glucopyranosyl carboxamides is thus justified and further syntheses and computational evaluation of such compounds will be reported in due course. 
Experimental
5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid (4)
To the solution of ethyl 5-phenyl-1,3,4-oxadiazole-2-carboxylate (3) (1.5 g, 6.91 mmol) in the 1:1 mixture of THF/water (78 mL) LiOH (248 mg; 10 mmol) was added and stirred at room temperature for 30 min. Then the mixture was acidified with c H 2 SO 4 and the precipitated product was filtered off, washed with water and dried on air. The product is light yellow crystals (900 mg, 68%, mp: decomposed over 230°C). 5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid (4) (400 mg, 2.11 mmol) was dissolved in thionyl chloride (4 mL) and refluxed for four hours. Then the mixture was concentrated in vacuum and used without any purification. 
5-carboxamide (9)
A solution of N-cyanocarbonyl derivative (8) Method A: To a solution of 2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl azide (6, 2.3 mmol) in dry dichloromethane (14 mL) a solution of PMe 3 in toluene (2.3 mL) was added and the mixture was stirred at room temperature. When the starting material was transformed (TLC, eluent: hexane/ethyl-acetate = 1:1) an acid chloride (2.3 mmol) was added to the mixture and stirred at room temperature for one day. Subsequently the mixture was concentrated in vacuum and the residue was purified by column chromatography (eluent hexane/ethyl-acetate = 2:1).
Method B: A solution of an aroyl-chloride (3.37 mmol) and tet-350 razole 9 (2.25 mmol) in dry toluene (15 mL) was stirred at 80°C for 2 h. Then the mixture was cooled and concentrated in vacuum and the residue was purified by column chromatography (eluent hexane/ethyl-acetate = 2:1).
By method A, starting from 6 (858 mg, 2.3 mmol) and 5-phenyl-1,3,4-oxadiazole-2-carbonyl chloride (5) 
N-[2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl]-1-(N 0 -hydroxycarbamimidoyl) formamide (12)
To the solution of N-cyanocarbonyl derivative (9) (100 mg, 0.25 mmol) in anhydrous pyridine (0.5 mL) hydroxylamine hydrochloride (43.6 mg, 0.63 mmol) was added, and the reaction was 420 stirred for one hour at 50°C. Subsequently it was acidified with 5% aqueous solution of HCl (10 mL) and extracted with ethyl acetate (3 Â 10 mL) and washed with water (2 Â 10 mL) The organic layer was dried over MgSO 4 and concentrated in vacuum. The residue was used without any purification. (77 mg, 71%).
N-[2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl]-1-(N 0 -benzoyloxycarbamimidoyl) formamide (13a)
A solution of 12 (77 mg, 0.178 mmol), benzoyl-chloride (23 ll, 0.196 mmol) and anhydrous pyridine (16 ll, 0.196 mmol) in anhydrous toluene (5 mL) was stirred for 24 h at 40°C. for a day. Subse-quently it was acidified with 5% aqueous solution of HCl (10 ml) and extracted with ethyl acetate (3 Â 10 ml) and washed with water (2 Â 10 mL). The organic layer was dried over MgSO 4 Method E: To the solution of a protected sugar derivative in dry methanol (or in dry methanol and dry chloroform) a catalytic amount of NaOMe (1 M solution in methanol) was added and stirred at room temperature. The progress of the reaction was monitored by TLC (chloroform/methanol = 9:1). When the starting material was consumed the mixture was neutralised with a cation exchange resin Amberlyst 15 (H + form) or with acetic acid, then the resin was filtered off and the solvent removed. The precipitated product was filtered off, washed with ether and dried. By method E, staring from 10a (90 mg, mmol) in the mixture of dry methanol (3 mL) and dry chloroform (1.5 mL) gave 11a as a white crystal (56 mg 
Staring from 10c (300 mg, 0.53 mmol) in the mixture of dry methanol (7 mL) and dry chloroform (7 mL) gave 11c as a white 
By method E, starting from 20b (90 mg, 0.16 mmol) in the mixture of dry methanol (2 mL) and dry chloroform (1 mL) to give 21b as white crystals (39 
General procedure for GP inhibition assay
Glycogen phosphorylase b was prepared from rabbit skeletal muscle according to the method of Fischer and Krebs 54 using 2-mercaptoethanol instead of L-cysteine, and recrystallized at least three times before use. The kinetic studies with glycogen phos-750 phorylase were performed as described previously. 41 Kinetic data for the inhibition of rabbit skeletal muscle glycogen phosphorylase by monosaccharide compounds were collected using different concentrations of a-D-glucose-1-phosphate (4, 6, 8, 10, 12 and 14 mM) and constant concentrations of glycogen (1% w/v) and AMP (1 mM). The enzymatic activities were presented in the form of double-reciprocal plots (Lineweaver-Burk) applying a nonlinear data-analysis programme. The inhibitor constants (K i ) were determined by Dixon plots, by replotting the slopes from the Lineweaver-Burk plots against the inhibitor concentrations. The means 760 of standard errors for all calculated kinetic parameters averaged to less than 10%. 55, 56 IC 50 values were determined in the presence of 4 mM glucose 1-phosphate, 1 mM AMP, 1% glycogen, and varying concentrations of an inhibitor.
ADMET property predictions
ADMET properties of the inhibitor analogues were predicted using the QikProp 3.5 program (Schrodinger, LLC) in normal mode. ALOGPS 2.1 45 was used to calculate supplementary log S and 'con- 
where P QP and P ALOGPS represent the QikProp and ALOGPS values, respectively, of a property P. The FAF-Drugs2 server 48 was used to extract any toxicity structural warnings for the ligands. 
